ARTICLE | Product Development
Fresh AIMMs for elite responders
AIMM's elite responder platform points to modified protein antigens in cancer
March 15, 2019 2:41 AM UTC
AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications.
The company is one of a handful of players mining the immune systems of cancer patients successfully treated with immunotherapies for therapeutic antibodies, and the first to disclose the targets it has found...